Skip to main content
OpenTrials
Completed

NCT Number: NCT04210583

RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity

Twelve month extension of a previous study of Multi-Polar RF and PEMF technologies for the treatment of vaginal laxity and for the treatment of the mons pubis and labia for improvement in skin laxity. The study will enroll up to 50 subjects who completed the Venus Fiore CS0716 study for the treatment of vaginal laxity and treatment of the mons pubis and labia for improvement in skin laxity. Subjects will be followed up at least six and twelve months post-treatment. Analysis will be performed on all subjects who complete the six-month and twelve month follow-up visits.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Dr. George Arnold

Markham, Ontario, L6B 0T1, Canada

About this study

Traditional non-surgical treatments to treat vaginal laxity include Kegel exercises or pelvic floor therapy with electrical stimulation of the vaginal musculature to promote muscle strength. Although surgery to tighten the vaginal introitus has been used, pain at the incision site leading to dyspareunia, sometimes for months, limits its use. Surgery is also recommended to reduce protuberant mons pubis and the outer labial lips of the labia majora. Most often, the mons pubis has been treated by fat reduction, either by liposuction or open excision along with a pubic skin lift. Surgery to reduce the excess skin of the labia majora tends to be avoided due to a lack of operative techniques and a fear of creating sexual dysfunction. Development of alternative methods of treatment, avoiding the usual surgical complications is warranted.

The use of non-ablative radiofrequency (RF) therapy has been used previously for the external and internal female genitalia without incident or complications. The use of Multi-Polar RF and PEMF technology was already demonstrated to be safe and efficient in delivering heat to the tissue. A previous study investigated the safety and efficacy of combining these technologies for the treatment of vaginal laxity and in the treatment of the mons pubis and labia for the improvement in skin laxity at four-months post-treatment. Efficacy and safety was confirmed up to 4-months post-treatment. (Venus FioreTM CS0716 study, unpublished raw data). However, the durability of the treatment is not known.

This study will investigate whether Multi-Polar RF and PEMF technologies for the treatment of vaginal laxity and for the treatment of the mons pubis and labia is safe and efficacious at six-months and twelve-months post-treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who have completed at least two treatments in the Venus Fiore™ CS0716 study and are at least 6 months post Fiore™ treatment.
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.
  • Sexual active and in a monogamous relationship

Exclusion criteria

  • Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
  • Having a permanent implant in the treatment area.
  • Prior use of collagen, fat injections and/or other methods of skin augmentation (enhancement with injected or implanted material) in the treatment areaduring the course of the study.
  • Use of retinoids such as oral Isotretinoin (Accutane®) during the course of the study.
  • Any other surgery in treated area within 12 months of initial treatment or during the course of the study.
  • Open laceration, abrasion or bleeding of any sort on the areas to be treated.
  • Active sexual transmitted disease (STD) (e.g. genital Herpes Simplex, condylomata) or vaginosis.
  • Chronic vulvar pain or vulvar dystrophy.
  • Use of immunosuppressive medications, including corticosteroids, during the course of the study.
  • Having any form of active cancer at the time of enrollment and during the course of the study.
  • Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the study, or healing process.
  • Participation in a study of another device or drug within 1 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria.
  • Evidence of active substance or alcohol abuse.
  • Having any stage 3-4 cystocele, rectocele, enterocele paravaginal defect or major pelvic organ prolapse beyond the hymenal ring.
  • Unstable dosages of medications such as antihypertensives or use of psychotropics that are known to affect sexuality.
  • Skin piercing in the treatment area.
  • Tattoos in the treatment area.
  • Prior procedure in the treatment area with laser or other device during the course of the study.
  • Use of an intrauterine device during the course of the study.

Treatment and study plan

Vulvovaginal treatment

Device

Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).

Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).

Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).

Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment).

Primary outcomes

  1. Long term safety (Follow-up for any AEs) of the Venus Fiore Fiore™ (MP)2 system in vaginal laxity and skin laxity of the mons pubis and labia.

    Time frame: 6 months

    AE assessment VLQ, FSFI, GRAS and GAIS (optional) Vaginal pH and vaginal smear (optional) Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)

Secondary outcomes

  1. long term safety of the Venus Fiore Fiore™ (MP)2 system in improving vaginal laxity and skin laxity of the mons pubis and labia.

    Time frame: 12 months

    AE assessment VLQ, FSFI, GRAS and GAIS (optional) Vaginal pH and vaginal smear (optional) Administer study treatment (optional: internal, mons pubis and/or labia treatment) Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)

Sponsors and collaborators

Lead sponsor

Venus Concept

Industry

Registry information

Official study title

Multi-Polar RF and PEMF Technologies for the Treatment of Vaginal Laxity and for Treatment of the Mons Pubis and Labia for Improvement of Skin Laxity: 12-Month Safety and Efficacy

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Dec 24, 2019
Registry last updated
Jun 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.